RECURRENT GLIOBLASTOMA

This early-phase trial tests whether combining two drugs—atezolizumab (which helps the immune system attack cancer) and cabozantinib (which blocks cancer cell growth)—can safely shrink tumors in adults with glioblastoma that has returned after standard treatment. About 6 particip…

This study tests a new triple combination therapy for adults with recurrent glioblastoma, an aggressive brain cancer. The treatment combines tumor-treating fields, laser ablation surgery, and an immunotherapy drug. The goal is to see if this approach is safe and feasible for 20 p…

This early-phase trial tests a new treatment for adults with glioblastoma or other high-grade gliomas that have come back after standard therapy. The treatment uses specially engineered immune cells (CAR-NK cells) that are designed to target two different markers on tumor cells a…

This early-stage study tests a new treatment for glioblastoma, an aggressive brain cancer that has come back after initial therapy. The approach combines an investigational drug (5-ALA) with focused ultrasound waves guided by brain imaging to target and damage tumor cells before …

This study tests whether the immunotherapy drug atezolizumab can help people with recurrent glioblastoma, a type of brain cancer that has come back after initial treatment. Researchers will look at genetic markers in tumors to see who might benefit most. About 80 adults with recu…

This study tests a combination of three drugs (pembrolizumab, olaparib, and temozolomide) in people whose glioblastoma brain tumor has come back after initial treatment. The goal is to see if the combination can shrink the tumor or slow its growth. About 78 adults will take part,…

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This early-phase trial tests a new treatment called EPC-003, which uses specially engineered immune cells (CAR-T cells) to target two proteins found on glioblastoma cells. About 14 adults with recurrent or refractory glioblastoma will receive the therapy directly into the brain's…

This study tests an experimental drug called pumitamig, alone or with other medicines, in adults whose glioblastoma (a fast-growing brain cancer) has returned after standard treatment. The goal is to see if these treatments can shrink tumors and control the disease. About 75 part…

This early-stage trial tests a new treatment called E-SYNC CAR T cells for people with a specific form of glioblastoma, an aggressive brain cancer. The therapy involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack the tumor, and infu…

This early-phase study tests a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a fast-growing brain cancer that has come back. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack the tumor. The main goals are to …

This early-phase trial tests a new treatment for adults with a type of recurrent brain cancer called glioblastoma. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to check safety and find the be…

This study tests a drug called sacituzumab govitecan in people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug targets a protein found on many cancer cells. Researchers want to see if it helps patients live longer compared to older tre…

This study tests a new approach for recurrent glioblastoma, a fast-growing brain cancer. Doctors place tiny radiation-emitting seeds directly into the tumor to kill cancer cells from the inside. The study will include 10 adults whose tumor has come back and is small enough (under…

This early-phase study tests a new treatment for adults with glioblastoma or high-grade glioma that has come back after standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to target two different markers on tumor cells at once, which may h…

This early-stage trial tests a new treatment called sonodynamic therapy for people with glioblastoma that has come back or is getting worse. The treatment combines a drug (5-ALA) that makes tumor cells sensitive to sound waves, with focused ultrasound waves that target and destro…

This early-phase trial tests a modified cold virus (DNX-2401) that targets and attacks brain cancer cells. The virus is loaded into donor stem cells and injected into an artery near the tumor. The study includes 36 adults with recurrent high-grade glioma and aims to find the safe…

This early-phase study tests a new drug called YSCH-01, alone or with another drug (atezolizumab), in 10 people whose glioblastoma brain cancer has returned. The main goal is to see if the treatment is safe and to measure how many participants are alive after one year. The study …

This early-stage study is testing whether a device called TheraSphere GBM is safe for people whose glioblastoma brain tumor has come back. About 36 adults with recurrent glioblastoma will receive the treatment. The main goal is to check for serious side effects and see if the pro…

This study tests a shorter, more intense radiation schedule for people whose glioblastoma (a severe brain cancer) has returned after standard treatment. About 28 adults will receive radiation 4 times a week for 1 to 3 weeks. The goal is to find the safest dose that controls the t…

This phase 3 trial tests whether a device called SonoCloud-9 can temporarily open the blood-brain barrier, allowing more chemotherapy (carboplatin) to reach brain tumors in people with recurrent glioblastoma. About 560 participants will be randomly assigned to receive either carb…

This early-phase study tests an experimental drug called CUE-102 in 18 adults whose glioblastoma (a type of brain cancer) has returned after initial treatment. The main goal is to check the drug's safety and find the best dose. Participants must have a specific genetic marker (HL…

This pilot study will use two types of PET scans and a powerful 7Tesla MRI to create detailed metabolic profiles of glioblastoma, both in newly diagnosed and recurrent tumors. Researchers will compare the scan results with lab tests on tumor tissue to better understand how these …

This study looks at how much of the drug T-DXd gets into brain tumors after being injected into the body. It includes 30 adults with brain cancer that has the HER2 protein. Researchers will measure drug levels in the tumor during surgery to see if it could be a useful treatment.

This study looks at MRI scans and a protein called decorin in 50 patients with glioblastoma, a serious brain cancer. The goal is to find out which patients might benefit from a drug called bevacizumab. Researchers will compare imaging and tissue samples to better understand tumor…

This study tests the drug troriluzole in people with recurrent glioblastoma, a type of brain cancer. Participants take the drug before surgery to see how it affects brain activity and glutamate levels in the tumor. The goal is to learn more about the drug's effects, not to treat …